METHODS
TYPE 2 DIABETES
This was a 12‐month, real‐world setting, prospective, one‐arm, single‐centre clinical study carried out from February 2016 to December 2019 that evaluated the safety and efficacy of switching from MDI to once daily IDegLira in selected patients with type 2 diabetes. The trial conformed to the recommendations of the Declaration of Helsinki and the International Council on Harmonization Good Clinical Practice norms with regard to medical research in humans. The protocol for this research was approved by the local institutional review board of the Békés County Central Hospital and also by the Hungarian National Medical Research Council's ethical review board. All participating patients provided signed informed consent before enrolment. The study is registered on 